Efficacy of resveratrol to supplement oral nifedipine treatment in pregnancy-induced preeclampsia. Issue 8 (November 2017)

• Record Type: Journal Article
• Authors: Ding, Jian; Kang, Yan; Fan, Yuqin; Chen, Qi
• Is Part Of: Endocrine connections. Volume 6:Issue 8(2017)
• Page Start: 595
• Page End: 600
• Publication Date: 2017-11
• Subjects: preeclampsia -- resveratrol -- nifedipine -- hypertension -- pregnancy; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EC-17-0130
• Languages: English
• ISSNs: 2049-3614

Abstract

Abstract : Objective: Preeclampsia (PE) is a complication affecting pregnant women worldwide, which usually manifests as severe maternal hypertension. Resveratrol (RESV), a naturally existing polyphenol, is known to exhibit beneficial effects in cardiovascular disease including hypertension. We evaluated the outcome of treatment combining oral nifedipine (NIFE) and RESV against PE. Design and methods: Using a randomized group assignment, 400 PE patients were enrolled and received oral treatments of either NIFE + RESV or NIFE + placebo. Primary endpoints were defined as time to control blood pressure and time before a new hypertensive crisis. Secondary endpoints were defined as the number of doses needed to control blood pressure, maternal and neonatal adverse effects. Results: Compared with the NIFE + placebo group, the time needed to control blood pressure was significantly reduced in NIFE + RESV group, while time before a new hypertensive crisis was greatly delayed in NIFE + RESV group. The number of treatment doses needed to control blood pressure was also categorically lower in NIFE + RESV group. No differences in maternal or neonatal adverse effects were observed between the two treatment groups. Conclusion: Our data support the potential of RESV as a safe and effective adjuvant of oral NIFE to attenuate hypertensive symptoms among PE patients.